Semaglutide has a reported half-life of roughly one week
As a highly selective GLP-1 receptor agonist, Semaglutide is designed to mimic the action of endogenous metabolic signaling hormones
Risks and considerations for microdosing semaglutide Microdosing semaglutide can have the following side effects: Lack of clinical evidence, safety data, and FDA approval Microdosing semaglutide is not recommended by the FDA for weight management or glycemic control
If diarrhea is so severe that it interferes with daily activities, work, or quality of life, treatment modification may be appropriate
For uncomplicated lower urinary tract infections, there is generally no medical reason to pause semaglutide
We see patients in Bend, Oregon and Seattle, Washington, and by telehealth across California, Oregon, and Washington